Serum sclerostin levels in Paget's disease and prostate cancer with bone metastases with a wide range of bone turnover

Bone

Volumn 51, Issue 1, 2012, Pages 153-157

  Yavropoulou, Maria P ^a   van Lierop, Antoon H ^a   Hamdy, Neveen A T ^a   Rizzoli, Rene ^b   Papapoulos, Socrates E ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Bone formation; Bone resorption; Paget's disease; Prostate cancer; Sclerostin

Indexed keywords

CARBOXY TERMINAL TELOPEPTIDE; PEPTIDE; PROCOLLAGEN C PROTEINASE; SCLEROSTIN;

ADULT; AGED; ARTICLE; BONE METASTASIS; BONE REMODELING; BONE TURNOVER; CELL COUNT; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OSSIFICATION; OSTEOBLAST; PAGET BONE DISEASE; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SYNDROME DELINEATION;

ADULT; AGED; BONE MORPHOGENETIC PROTEINS; BONE NEOPLASMS; BONE RESORPTION; FEMALE; GENETIC MARKERS; HUMANS; MALE; MIDDLE AGED; OSTEITIS DEFORMANS; PROSTATIC NEOPLASMS; YOUNG ADULT;

EID: 84861217590     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2012.04.016     Document Type: Article

References (47)

1. Bonewald L.F. The amazing osteocyte. J Bone Miner Res 2011, 26:229-238.
2. van Bezooijen R.L., Roelen B.A., Visser A., van der Wee-Pals L., de Wilt E., Karperien M., et al. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med 2004, 199:805-814.
3. Winkler D.G., Sutherland M.K., Geoghegan J.C., Yu C., Hayes T., Skonier J.E., et al. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 2003, 22:6267-6276.
4. Li X., Zhang Y., Kang H., Liu W., Liu P., Zhang J., et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 2005, 280:19883-19887.
5. van Bezooijen R.L., Svensson J.P., Eefting D., Visser A., van der Horst G., Karperien M., et al. Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation. J Bone Miner Res 2007, 22:19-28.
6. Balemans W., Ebeling M., Patel N., Van H.E., Olson P., Dioszegi M., et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 2001, 10:537-543.
7. Brunkow M.E., Gardner J.C., Van N.J., Paeper B.W., Kovacevich B.R., Proll S., et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet 2001, 68:577-589.
8. Balemans W., Patel N., Ebeling M., Van H.E., Wuyts W., Lacza C., et al. Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet 2002, 39:91-97.
9. Staehling-Hampton K., Proll S., Paeper B.W., Zhao L., Charmley P., Brown A., et al. A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population. Am J Med Genet 2002, 110:144-152.
10. Lin C., Jiang X., Dai Z., Guo X., Weng T., Wang J., et al. Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/beta-catenin signaling. J Bone Miner Res 2009, 24:1651-1661.
11. O'Brien C.A., Plotkin L.I., Galli C., Goellner J.J., Gortazar A.R., Allen M.R., et al. Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS One 2008, 3:e2942.
12. Robling A.G., Niziolek P.J., Baldridge L.A., Condon K.W., Allen M.R., Alam I., et al. Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J Biol Chem 2008, 283:5866-5875.
13. Nakashima T., Hayashi M., Fukunaga T., Kurata K., Oh-Hora M., Feng J.Q., et al. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med 2011, 17:1231-1234.
14. Xiong J., Onal M., Jilka R.L., Weinstein R.S., Manolagas S.C., O'Brien C.A. Matrix-embedded cells control osteoclast formation. Nat Med 2011, 17:1235-1241.
15. Wijenayaka A.R., Kogawa M., Lim H.P., Bonewald L.F., Findlay D.M., Atkins G.J. Sclerostin Stimulates Osteocyte Support of Osteoclast Activity by a RANKL-Dependent Pathway. PLoS One 2011, 6:e25900.
16. Li X., Ominsky M.S., Warmington K.S., Morony S., Gong J., Cao J., et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 2009, 24:578-588.
17. Ominsky M.S., Vlasseros F., Jolette J., Smith S.Y., Stouch B., Doellgast G., et al. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res 2010, 25:948-959.
18. Padhi D., Jang G., Stouch B., Fang L., Posvar E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 2011, 26:19-26.
19. van Lierop A.H., Witteveen J.E., Hamdy N.A., Papapoulos S.E. Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls. Eur J Endocrinol 2010, 163:833-837.
20. Durosier C., van Lierop A., Ferrari S., Chevally T., Papapoulos S., Rizolli R. Circulating Sclerostin Correlates to Bone Mineral Mass, Micro-Structure and Turnover in Healthy Elderly Men and Women. J Bone Miner Res 2011, 26(s1):S221.
21. van Lierop A.H., Hamdy N.A., Hamersma H., van Bezooijen R.L., Power J., Loveridge N., et al. Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnover. J Bone Miner Res 2011, 26:2804-2811.
22. Drake M.T., Srinivasan B., Modder U.I., Peterson J.M., McCready L.K., Riggs B.L., et al. Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab 2010, 95:5056-5062.
23. Charhon S.A., Chapuy M.C., Delvin E.E., Valentin-Opran A., Edouard C.M., Meunier P.J. Histomorphometric analysis of sclerotic bone metastases from prostatic carcinoma special reference to osteomalacia. Cancer 1983, 51:918-924.
24. Ikeda I., Miura T., Kondo I. Pyridinium cross-links as urinary markers of bone metastases in patients with prostate cancer. Br J Urol 1996, 77:102-106.
25. Pelger R.C., Hamdy N.A., Zwinderman A.H., Nijeholt A.A., Papapoulos S.E. Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton. Bone 1998, 22:403-408.
26. Percival R.C., Urwin G.H., Harris S., Yates A.J., Williams J.L., Beneton M., et al. Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption. Eur J Surg Oncol 1987, 13:41-49.
27. Urwin G.H., Percival R.C., Harris S., Beneton M.N., Williams J.L., Kanis J.A. Generalised increase in bone resorption in carcinoma of the prostate. Br J Urol 1985, 57:721-723.
28. Kim S., Kim H., Yoon S., Lee C., Lim S., Rhe Y. Decreased Renal Function but not Liver Function Overpowers the Circulating Sclerostin Level. J Bone Miner Res 2011, 26(Suppl. 1):S357-S358.
29. Mirza F.S., Padhi I.D., Raisz L.G., Lorenzo J.A. Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. J Clin Endocrinol Metab 2010, 95:1991-1997.
30. Polyzos S.A., Anastasilakis A.D., Bratengeier C., Woloszczuk W., Papatheodorou A., Terpos E. Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women-the six-month effect of risedronate and teriparatide. Osteoporos Int 2011, [epub ahead of print].
31. Sheng Z., Tong D., Ou Y., Zhang H., Zhang Z., Li S., et al. Serum sclerostin levels were positively correlated with fat mass and bone mineral density in central south Chinese postmenopausal women. Clin Endocrinol 2011, [epub ahead of print].
32. Chung Y.E., Lee S.H., Lee S.Y., Kim S.Y., Kim H.H., Mirza F.S., et al. Long-term treatment with raloxifene, but not bisphosphonates, reduces circulating sclerostin levels in postmenopausal women. Osteoporos Int 2011, [epub ahead of print].
33. Kaji H., Imanishi Y., Sugimoto T., Seino S. Comparisons of serum sclerostin levels among patients with postmenopausal osteoporosis, primary hyperparathyroidism and osteomalacia. Exp Clin Endocrinol Diabetes 2011, 119:440-444.
34. Morse L.R., Sudhakar S., Danilack V., Tun C., Lazzari A., Gagnon D.R., et al. Association between sclerostin and bone density in chronic SCI. J. Bone Miner. Res. 2011, [epub ahead of print].
35. Modder U.I., Hoey K.A., Amin S., McCready L.K., Achenbach S.J., Riggs B.L., et al. Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res 2011, 26:373-379.
36. Garcia-Martin A., Rozas-Moreno P., Reyes-Garcia R., Morales-Santana S., Garcia-Fontana B., Garcia-Salcedo J.A., et al. Circulating Levels of Sclerostin Are Increased in Patients with Type 2 Diabetes Mellitus. J Clin Endocrinol Metab 2011, 97:234-241.
37. Ardawi M.S., Al-Kadi H.A., Rouzi A.A., Qari M.H. Determinants of serum sclerostin in healthy pre- and postmenopausal women. J Bone Miner Res 2011, 26:2812-2822.
38. Amrein K., Amrein S., Drexler C., Dimai H.P., Dobnig H., Pfeifer K., et al. Sclerostin and its association with physical activity, age, gender, body composition, and bone mineral content in healthy adults. J Clin Endocrinol Metab 2012, 97:148-154.
39. Gatti D., Viapiana O., Adami S., Idolazzi L., Fracassi E., Rossini M. Bisphosphonate treatment of postmenopausal osteoporosis is associated with a dose dependent increase in serum sclerostin. Bone 2011, [epub ahead of print].
40. Marshall M.J., Evans S.F., Sharp C.A., Powell D.E., McCarthy H.S., Davie M.W. Increased circulating Dickkopf-1 in Paget's disease of bone. Clin Biochem 2009, 42:965-969.
41. Naot D., Bava U., Matthews B., Callon K.E., Gamble G.D., Black M., et al. Differential gene expression in cultured osteoblasts and bone marrow stromal cells from patients with Paget's disease of bone. J Bone Miner Res 2007, 22:298-309.
42. Heiland G.R., Zwerina K., Baum W., Kireva T., Distler J.H., Grisanti M., et al. Neutralisation of Dkk-1 protects from systemic bone loss during inflammation and reduces sclerostin expression. Ann Rheum Dis 2010, 69:2152-2159.
43. Barnes J., Anthony C.T., Wall N., Steiner M.S. Bone morphogenetic protein-6 expression in normal and malignant prostate. World J Urol 1995, 13:337-343.
44. Dai J., Keller J., Zhang J., Lu Y., Yao Z., Keller E.T. Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism. Cancer Res 2005, 65:8274-8285.
45. Ohyama Y., Nifuji A., Maeda Y., Amagasa T., Noda M. Spaciotemporal association and bone morphogenetic protein regulation of sclerostin and osterix expression during embryonic osteogenesis. Endocrinology 2004, 145:4685-4692.
46. Sutherland M.K., Geoghegan J.C., Yu C., Winkler D.G., Latham J.A. Unique regulation of SOST, the sclerosteosis gene, by BMPs and steroid hormones in human osteoblasts. Bone 2004, 35:448-454.
47. Menaa C., Reddy S.V., Kurihara N., Maeda H., Anderson D., Cundy T., et al. Enhanced RANK ligand expression and responsivity of bone marrow cells in Paget's disease of bone. J Clin Invest 2000, 105:1833-1838.